Tharimmune, Inc.
Monday, June 03, 2024
Multiple Therapeutics
Company Presentation Theater 3
Tharimmune (nasdaq: THAR) is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company's lead clinical-stage asset, TH104 is known to suppress chronic, debilitating pruritis or “uncontrollable itching” in PBC, a rare and orphan liver disease with no known cure. The Company’s early-stage IO pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets (PD-1, HER2, HER3) in multiple solid tumors. Tharimmune has a license agreement with OmniAb, Inc. to access the company’s antibody discovery technology platform against specified targets.
Company Website:
https://tharimmune.com/
Lead Product in Development:
TH104 is embedded with nalmefene onto a proprietary transdermal buccal film which easily adheres to the inside of the mouth. This endows TH104 with key features making it an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. The molecule has a dual mechanism of action affecting both the µ-opioid and kappa opioid receptors. These opioid receptors when stimulated and/or inhibited by the body's natural ligands have been known to be involved in the body's itch circuitry.
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Multiple
Exchange
NASDAQ
Ticker
THAR
Company HQ City
Bridgewater
Company HQ State
New Jersey
Company HQ Country
United States
CEO/Top Company Official
Randy Milby
Development Phase of Primary Product
Phase II
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())